Recurrent pregnancy loss (RPL) is a well-recognized complication of antiphospholipid syndrome (APS). First line therapy consists of low dose aspirin and heparin. Despite conventional therapy some women fail to achieve a successful pregnancy outcome. We describe the case of a patient who had two live births following intravenous immunoglobulin therapy despite previous failure with conventional therapy for RPL in the setting of APS. We will summarize the available literature on intravenous immunoglobulin for this indication.
MeroniPL, TedescoF, LocatiM. Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view.Lupus2010; 19: 453–356
5.
LubbeWF, ButlerWS, PalmerSJ, LigginsGC. Fetal survival after prednisone suppression of maternal lupus-anticoagulant.Lancet1983; 1: 1361–3
CarrerasLD, PerezGN, VegaHR, CasavillaF. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin.Lancet1988; 2: 393–4
8.
MarzuschK, DietlJ, KleinR. Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin.Acta Obstet Gynecol Scand1996; 75: 922–6
9.
ClarkAL, BranchDW, SilverRM. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy.Obstet Gynecol1999; 93: 437–41
10.
SpinnatoJA, ClarkAL, PierangeliSS, HarrisEN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy.Am J Obstet Gynecol1995; 172: 690–4
11.
ValensiseH, VaqueroE, De CarolisC. Normal fetal growth in women with antiphospholipid syndrome treated with high dose intravenous immunoglobulin.Prenat Diagn1995; 15: 509–17
12.
KajaaR, JulkunenH, AmmalaP, PalosuoT, KurkiP. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies.Acta Obstet Gynecol Scand1993; 72: 63–6
13.
PerriconeR, De CarolisC, KroeglerB. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion.Rheumatology2008; 47: 646–51
14.
ShettyS, GhoshK. Antiphospholipid antibodies and other immunological causes of recurrent foetal loss - a review of literature of various therapeutic protocols.Am J Reprod Immunol2009; 62: 9–24
15.
BranchDW, PeacemanAM, DruzinM. A multicentre, placebo-controlled pilot study of intravenous immunoglobulin treatment of antiphospholipid syndrome during pregnancy.Am J Obstet Gynecol2000; 182: 122–7
16.
TrioloG, FerranteA, CicciaF. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies.Arthritis Rheum2003; 48: 728–31
17.
DendrinosS, SakkasE, MakrakisE. Low-molecular weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid syndrome.Int J Gynecol Obstet2009; 104: 223–5
18.
EmpsonMB, LassereM, CraigJC, ScottJR. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.Cochrane Database Syst Rev2005: CD002859. DOI: 10.1002/14651858.CD002859.pub2
19.
TrioloG, FerranteA, Accardo-PalumboA. IVIG in APS pregnancy.Lupus2004; 13: 731–5
20.
DiejomaohMF, Al-AzemiMM, BandarA. A favourable outcome of pregnancies in women with primary and secondary recurrent pregnancy loss associated with antiphospholipid syndrome.Arch Gynecol Obstet2002; 266: 61–6
21.
WapnerRJ, CowchockS, ShapiroSS. Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions.Am J Obstet Gynecol1989; 161: 1271–2
22.
ChangP, MilarD, TsangP. Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: a case report.Am J Perinatol2006; 23: 125–9
23.
ErkanD, PatelS, NuzzoM. Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers.Rheumatology2008; 47: iii23–27
24.
FoudaUM, SayedAM, AdbouAA. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome.Int J Gynecol Obstet2011; 112: 211–5
25.
FoudaUM, SayedAM, RamadanDI, FoudaIM. Efficacy and safety of two doses of low molecular weight heparin (enoxaparin) in pregnancy women with a history of recurrent abortion secondary to antiphospholipid syndrome.J Obstet Gynecol2010; 30: 842–6
26.
PyneD, EhrensteinM, MorrisV. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases.Rheumatology2002; 41: 367–74
27.
MackayIR, RosenFS. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin.N Engl J Med2001; 345: 747–55
28.
MakA, CheungM, CheakA, HoR. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression.Rheumatology2010; 49: 281–88
29.
Report on the use of intravenous immunoglobulin (IVIG) for 2009-2010, National Blood Authority, Australia. See http://www.nba.gov.au/ivig/index.html (last checked 25 February 2013)
30.
Jurisdictional Blood Committee, for and on behalf of the Health Minister's Conference. Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia.Second Edition.Canberra: Commonwealth of Australia, 2012
31.
CSL Limited.Intragam P Product Information, 2012. See http://www.csl.com.au (last checked 25 February 2013)
32.
BranchDW, SilverRM, PorterTF. Obstetric antiphospholipid syndrome: current uncertainties should guide our way.Lupus2010; 19: 446–52
